AstraZeneca gains full global rights to AbelZeta’s CAR-T therapy in $630M deal

Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy

LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates

CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China

CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Kelun-Biotech secures IND nod for innovative cancer therapy SKB105 in China

Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001

Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours

CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38

Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613

The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis

GSK’s experimental lung cancer drug gains FDA orphan drug status

GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization